Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 · New England Journal of Medicine · 5,710 citations
https://doi.org/10.1056/nejmoa065044
P
Piotr Tomczak
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
24.9K
Citations
42
h-index
86
i10-index
Piotr Tomczak is an academic researcher from Poznan University of Medical Sciences. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Cancer Genomics and Diagnostics. The author has an h-index of 42, co-authored 165 publications.
ORCID: 0000-0002-8816-5525Papers by this author
worksPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
https://doi.org/10.1016/s1470-2045(19)30863-0
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
2013 · British Journal of Cancer · 154 citations
https://doi.org/10.1038/bjc.2013.69
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
2021 · Breast Cancer Research and Treatment · 97 citations
https://doi.org/10.1007/s10549-021-06367-5
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 · European Journal of Cancer · 46 citations
https://doi.org/10.1016/j.ejca.2017.05.010
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
2018 · European Journal of Cancer · 38 citations
https://doi.org/10.1016/j.ejca.2018.02.009
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat